Solcoseryl - instructions for use, dose, side effects, contraindications

Preparation solkoseril is deproteinized gemodializat containing a wide range of low-molecular components of cell mass and blood serum of calves milk with a molecular weight of 5000 D (glycoproteins, nucleosides and nucleotides, oligopeptides, amino acids).

It is established that SOLKOSERIL has the following properties:

- improves the transport of oxygen and glucose to cells in the environment hypoxia;

- increases the synthesis of intracellular ATP and promotes an increase in the proportion of aerobic glycolysis and oxidative phosphorylation;

- activates reparative and regenerative processes in tissues;
- stimulates the proliferation of fibroblasts and the synthesis of collagen wall vessels.

Pharmacokinetics:

With the help of pharmacokinetic methods, it is impossible to study the pharmacokinetic parameters of the SOLKOSERIL preparation.

Indications:

- violations of peripheral arterial or venous circulation (occlusive diseases of peripheral arteries in stages III-IV Fonteynu, chronic venous insufficiency, accompanied by trophic disorders);

- violations of cerebral metabolism and blood circulation (ischemic and hemorrhagic stroke, craniocerebral trauma).

Contraindications:

- established hypersensitivity to dialyzes of calf blood; since SOLKOSERIL contains parahydroxybenzoic acid derivatives (E 216, E 218) used as preservatives, as well as traces of benzoic acid (E 210), the drug should not be used in the presence of an allergic reaction to the listed components;

- Children under 18 years of age (due to lack of data);

- pregnancy and lactation (due to lack of data).

Carefully:Hyperkalemia, renal failure, heart rhythm disturbances, concomitant intake of potassium preparations (since SOLKOSERIL contains potassium); oliguria, anuria, pulmonary edema, severe heart failure.

Dosing and Administration:

Intravenous (drip or jet), intramuscularly.

If the patient's clinical condition allows, it is recommended to inject the Solcoseryl solution intravenously drip, rather than intravenously, by jet or intramuscular injection.

Intravenous drip introduction.

Solcoseryl solution for intravenous drip administration should be applied at a dilution of at least 1: 1 0.9% solution of sodium chloride or 5% solution of dextrose (glucose) and injected slowly. Solcoseryl should not be diluted with potassium-containing intravenous solutions.

Intravenous fluid administration.

Solcoseryl solution for intravenous fluid administration should be applied at a dilution of at least 1: 1 0.9% solution of sodium chloride or 5% solution of dextrose (glucose). Solcoseryl should not be diluted with potassium-containing intravenous solutions. Solcoseryl solution should be administered slowly (at least 2 minutes) to prevent a rapid increase in the level of potassium in the blood. If the volume of diluted Solcoseryl solution with intravenous injection exceeds 20 ml, the drug is administered intravenously drip.

Intramuscular injection.

If intravenous administration is not possible, the drug can be administered intramuscularly without diluting 2 ml per day.

Recommended dosages:

Occlusion diseases of peripheral arteries in stages III-IV Fontaine: for 850 mg of Solcoseryl (20 ml of undiluted preparation) daily intravenously.

The duration of therapy is up to 4 weeks and is determined by the clinical picture of the disease.

Chronic venous insufficiency with trophic disorders: 425 mg Solcoseryl (10 ml undiluted drug) intravenously 3 times a week. The duration of therapy is no more than 4 weeks and is determined by the clinical picture of the disease. In the presence of local trophic tissue disorders, simultaneous therapy with Solcoseryl gel and then Solcoseryl ointment is recommended.

Craniocerebral trauma, metabolic and cerebral diseases of the brain: 425 - 850 mg Solcoseryl (10 - 20 ml undiluted preparation) intravenously daily for 10 days. Then 85 mg (2 ml of undiluted preparation) intramuscularly or intravenously for up to 30 days.

Side effects:

In rare cases, allergic reactions may develop (urticaria, hyperemia and edema at the injection site, fever). In this case, it is necessary to stop the use of the drug and prescribe symptomatic treatment.

Overdose:

Information about symptoms of an overdose is absent.

Interaction:

SOLKOSERIL should not be mixed when administered with other medicinal products (especially withphytoextracts).

Pharmaceutically incompatible with parenteral forms of the extract Ginko biloba, naphthydrofuryl, benzyclane fumarate.

It is used with caution with drugs that raise the level of potassium in the blood (potassium preparations, potassium-sparing diuretics, inhibitors of the angiotensin-converting enzyme).

Effect on the ability to drive transp. cf. and fur:The use of the drug does not affect the performance of potentially hazardous activities requiring an increased concentration of attention and speed of psychomotor reactions (vehicle management, work with moving mechanisms).

Form release / dosage:The solution for intravenous and intramuscular injection is 42.5 mg / ml.

Packaging:

By 2 or 5 ml into ampoules from a neutral hydrolytically stable dark glass (Class I by He.F.) with a white point above the fault site. 5 ampoules per contour cell polymer package L contour pack with the drug in 5 ml ampoules or 5 contour packs with the preparation in 2 ml ampoules together with instructions for use in a cardboard pack.

Storage conditions:

In the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

5 years from the date of production.Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:П N015224 / 03

Date of registration:17.01.2008

The owner of the registration certificate:MEDA Pharmaceuticals Switzerland GmbHMEDA Pharmaceuticals Switzerland GmbH Switzerland

Manufacturer: & nbsp

LEGACY PHARMACEUTICALS SWITZERLAND, GmbH Switzerland

Representation: & nbspMEDA PHARMA LLCMEDA PHARMA LLC

Information update date: & nbsp21.12.2015

Illustrated instructions

Instructions

Solcoseryl (Solcoseryl®)